Länsförsäkringar

Altris develops sodium-ion battery cathode material that is made entirely of abundant and environmental materials. The company's cathode material, Fennac®, is designed for efficient energy storage, promoting a greener future. Fennac® is made from iron, sodium, carbon, and nitrogen—all readily available and non-toxic materials. This allows Altris to produce batteries that are not only more sustainable but also safe for widespread use. Altris places a strong emphasis on sustainability by using abundant and low-cost materials, reducing dependency on scarce and geopolitically sensitive resources like lithium, cobalt, and nickel. Their technology is designed to be more environmentally friendly from production through to the end-of-life recycling process.

THE NEW STANDARD HAS ARRIVED. Wrapp is The New Standard for rewarding purchases and customer loyalty. The end to an era of irrelevant advertising and outdated memberships. Wrapp connects to our users’ payment cards, and analyzes transactions to learn their buying behavior. This way, our users only get rewards from brands they're interested in. And by sticking to cashback returns, we make sure they get rewards they actually find useful. Simply put, we put purchasing power in the hands of consumers, and meaningful marketing in the hands of brands.

Vindmark Group is to manufacture and sell innovative wind turbines with high and cost effective towers combined with longer rotor blades for third parties or for self-financed projects. Vindmark controls the entire value chain from prospecting to construction and construction of wind turbines.

Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes. Adenovir Pharma was founded by researchers at the department of Virology, Umeå University, Sweden and P.U.L.S. AB which acts as an incubator and financer for early stage projects within life science. Adenovir Pharma is located in Helsingborg Sweden in one of Europe’s premier biotechnology regions, Medicon Valley. The initial development has been conducted at the University of Lund, Department of Organic Chemistry and at the University of Umeå, Department of Virology and in collaboration with P.U.L.S. AB and external service providers. With unique patented technology and own product concepts, Adenovir Pharma aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC).